Myocardial MIBG scintigraphy: A useful clinical tool

Ines Fröhlich*, Nico J. Diederich, Wilfried Pilloy, Michel Vaillant

*Corresponding author for this work

    Research output: Contribution to journalArticleResearchpeer-review

    16 Citations (Scopus)


    Meta-iodbenzylguanidine scintigraphy (MIBG scintigraphy) shows reduced uptake in idiopathic Parkinson's disease (IPD), idiopathic REMsleep behavior disorder (IRBD) and Lewy body dementia (LBD), but not in other parkinsonian or dementia syndromes. We retrospectively reevaluated 50 patients. Concordance rate between last clinical diagnosis and scintigraphy diagnosis was only given in two-thirds of the patients. Confounding factors were: decreasing heart/mediastinum ratio (HMR) with progressive age, higher HMR in women and possibly interference with antihypertensive medication. Standardization of the methods and precise clinical guidelines are warranted for better clinical use.

    Original languageEnglish
    Pages (from-to)403-406
    Number of pages4
    JournalNeurological Sciences
    Issue number3
    Publication statusPublished - Jun 2010


    • Idiopathic Parkinson disease
    • Myocardial scintigraphy


    Dive into the research topics of 'Myocardial MIBG scintigraphy: A useful clinical tool'. Together they form a unique fingerprint.

    Cite this